Core Insights - The article highlights the growing focus on future industries in China, as emphasized in the "14th Five-Year Plan," which aims to cultivate and expand emerging industries and future sectors [1] - It discusses the importance of exploring diverse technological routes, typical application scenarios, feasible business models, and market regulatory rules to drive economic growth through sectors like quantum technology, biomanufacturing, hydrogen energy, nuclear fusion, brain-computer interfaces, embodied intelligence, and 6G mobile communication [1] Group 1: Market Trends - The article notes that over 381 concept stocks have seen a decline in shareholder numbers compared to the end of Q3, with more than 40 companies experiencing a decrease, and 27 companies showing a decline exceeding 3% [1] - 福晶科技 (Fujing Technology) has seen a significant drop in shareholder numbers, with a decrease of nearly 26% compared to the end of Q3 [1] Group 2: Investment Opportunities - Among the 27 companies with a shareholder decline over 3%, only 10 companies have recorded a year-to-date increase of less than 19%, indicating potential for price recovery in the future industry sector [1] - The table lists several companies with their respective year-to-date performance and shareholder decline percentages, highlighting potential stocks for future investment, such as 致远新能 (Zhiyuan New Energy) with a 3.59% increase and a 10.40% decline in shareholder numbers [2]

证券日报网讯12月25日，戴维医疗（300314）发布公告称，公司医用空气压缩机获浙江省药监局延续注 册，注册证编号浙械注准20212080048，有效期至2031.2.2，属Ⅱ类器械，供医疗机构为呼吸机提供压缩 空气源，可继续产销。 ...

财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：钟离 格隆汇12月25日丨戴维医疗(300314.SZ)公布，近日取得由浙江省药品监督管理局颁发的1项《医疗器械 注册证》，公司产品医用空气压缩机完成了延续注册。 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-091 宁波戴维医疗器械股份有限公司 关于公司部分医疗器械产品完成延续注册的公告 特此公告。 宁波戴维医疗器械股份有限公司 董事会 2025年12月25日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得由 浙江省药品监督管理局颁发的1项《医疗器械注册证》，公司产品医用空 气压缩机完成了延续注册，具体如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 医用空气压缩 | 浙械注准 | 2031.2.2 | Ⅱ类 | 供医疗机构，制取医用压缩空 | | | 机 | 20212080048 | | | 气，为呼吸机或类似呼吸通气 | | | | | | | 系统提供压缩空气源。 | 本次延续注册的完成，使得公司可以继续生产和销售医用空气压缩机， 对公司未来经营将产生积极影响。上述产品的实际销售情况取决于未来市 场 ...

（文章来源：证券日报） 证券日报网讯 12月23日，戴维医疗在互动平台回答投资者提问时表示，截至2025年12月19日，公司股 东总户数约为19100户。 ...

有投资者在互动平台向戴维医疗提问："董秘，您好！请问公司截至12月20日公司的股东人数是多少？ 谢谢。" 来源：市场资讯 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 针对上述提问，戴维医疗回应称："您好，截至2025年12月19日，公司股东总户数约为19100户左右，感 谢您的关注。" ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-090 宁波戴维医疗器械股份有限公司 关于全资子公司申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁波 维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日取得由浙江省 药品监督管理局颁发的1项《受理通知书》，受理号为：械受20254041167。 具体情况如下： | | 一次性腔镜用电动直 | | 本产品适用于胃、肠组织的离断、切除和吻 | | --- | --- | --- | --- | | | 线型切割吻合器及组 | II 类 | 合，也可用于肺、肝脏、胆囊、肾脏、子宫 | | 序号 1 | 产品名称 件 | 注册分类 | 临床用途 及附件的离断和切除。 | 维尔凯迪开发的一次性腔镜用电动直线型切割吻合器及组件是腔镜手术 的重要器械之一，替代传统的手工缝合，利用钛钉对组织进行离断或吻合， 其通过动力传感在击发吻合钉的同时，于两吻合钉之间切断组织，使手术过 程更加快速、精确、高效，同时，电动吻合口组 ...

Core Insights - The open stapler market in China is experiencing a declining trend, with the market size expected to reach 1.41 billion yuan in 2024, a year-on-year decrease of 2.1% [1][10] - The decline is primarily attributed to the shift towards minimally invasive surgical techniques, with laparoscopic staplers becoming the mainstream choice due to their advantages in reducing trauma and improving recovery times [1][10] - Despite the decline, open staplers still hold irreplaceable value in grassroots medical settings and complex surgeries, indicating potential stabilization in market size [1][10] Industry Overview - Open staplers are primarily used in traditional open surgeries, offering advantages such as quick suturing, ease of use, and reduced risk of cross-infection [3] - The types of open staplers include linear staplers, circular digestive tract staplers, and others, with a growing trend towards laparoscopic staplers due to their enhanced safety and efficiency [4][5] Market Dynamics - The open stapler market in China saw a decline from 1.53 billion yuan in 2020 due to the pandemic, with a recovery in 2021 followed by a projected decline from 2022 to 2024 [10][11] - The global open stapler market is expected to reach 3.34 billion USD by 2024, reflecting a slow growth rate influenced by the expansion of laparoscopic staplers [10] Competitive Landscape - The market remains competitive, with foreign giants like Johnson & Johnson and Medtronic dominating the high-end segment due to their technological advantages [12] - Domestic companies are leveraging local production to control costs and meet the needs of hospitals, with some products nearing the performance of foreign brands [12] Key Players - Notable companies in the open stapler industry include Dongxing Medical, Lepu Medical, and David Medical, which are focusing on product innovation and cost-effective solutions [2][12][13] Development Trends - Continuous optimization of technology in open staplers is expected, focusing on safety, efficiency, and precision [14] - The integration of automation and standardization features is anticipated, aiming to reduce reliance on surgeon experience and enhance surgical quality [15] - Future demand will likely concentrate on specific fields, particularly in grassroots healthcare and complex surgical scenarios, emphasizing differentiated competition [16]

（编辑 任世碧） 证券日报网讯 12月18日晚间，戴维医疗发布公告称，公司全资子公司宁波维尔凯迪医疗器械有限公司 （简称"维尔凯迪"）于近日取得由浙江省药品监督管理局颁发的1项《医疗器械注册证》，维尔凯迪产 品一次性使用腔镜切割吻合器及组件完成了延续注册。 ...

格隆汇12月18日丨戴维医疗(300314.SZ)公布，全资子公司宁波维尔凯迪医疗器械有限公司（简称"维尔 凯迪"）于近日取得由浙江省药品监督管理局颁发的1项《医疗器械注册证》，维尔凯迪产品一次性使用 腔镜切割吻合器及组件完成了延续注册。 ...